First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) remains negative
Q1 FY2026 property, plant & equipment (net) was $1.17M, compared with $0 a year earlier.
Context
- Property, plant & equipment (net) amounted to 0.4% of total assets at the end of Q1 FY2026.
- Property, plant & equipment (net) increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 13.89M USD
- Year-over-year change
- -14.4%
- 2-year CAGR
- -12.8%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.89M | -14.4% |
| FY2024 | 2024-12-31 | 16.23M | -11.2% |
| FY2023 | 2023-12-31 | 18.27M | — |
Property, Plant & Equipment (Net) vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 property, plant & equipment (net) of $1.17M is the 6th highest of the 10 companies compared; the peer median is $2.39M.
- Property, plant & equipment (net) amounts to 0.4% of total assets for TRAX, versus a peer median of 0.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $19.58M | -4.0% | -11.9% | 8.2% | |
| Mar 2026 | $13.32M | -15.0% | -11.4% | 4.0% | |
| Jun 2026 | $6.92M | — | — | 5.4% | |
| Mar 2026 | $2.89M | +206.5% | — | 1.5% | |
| Mar 2026 | $2.39M | -27.6% | +86.2% | 0.6% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $1.17M | — | — | 0.4% |
| Mar 2026 | $983K | -36.2% | -13.8% | 0.5% | |
CLYMClimb Bio, Inc. | Mar 2026 | $697K | +54.5% | +19.0% | 0.5% |
| Mar 2026 | $530K | -37.6% | -6.0% | 0.4% | |
| Sep 2026 | $262K | -58.5% | -30.1% | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $2.39M | -21.3% | -11.4% | 0.6% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.